Johnson & Johnson beats sales estimates on pharma strength
reuters.com
news
2022-10-18 10:36:02

The Johnson & Johnson logo is displayed on a screen on the floor of the New York Stock Exchange (NYSE) in New York, U.S., May 29, 2019. REUTERS/Brendan McDermidOct 18 (Reuters) - Johnson & Johnson (JNJ.N) on Tuesday beat analysts' estimates for third-quarter sales, helped by strong demand for its cancer drug Darzalex and Crohn's disease drug Stelara.The U.S. healthcare conglomerate tightened its full-year adjusted profit forecast range.J&J is the first drugmaker and medical devices firm to report third-quarter earnings and the maintained forecast could be seen as a sign of demand resiliency.
